Showing 1451-1460 of 1587 results for "".
- Aaron Burton Named CEO at Scitonhttps://modernaesthetics.com/news/aaron-burton-named-ceo-at-sciton/2472888/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently o
- FDA Sets November PDUFA Date for DaxibotulinumtoxinA from Revancehttps://modernaesthetics.com/news/fda-sets-november-pdufa-date-for-daxibotulinumtoxina-from-revance/2472880/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- Candela Launches Exceed Medical Microneedling Systemhttps://modernaesthetics.com/news/candela-launches-exceed-medical-microneedling-system/2472878/Candela Corporation has entered into an exclusive collaboration agreement with MT.DERM GmbH for the commercialization of MT.DERM's medical microneedling products. Under the terms of the agreement, Candela will commercialize the Exceed medical microneedling system globally, with a first launch
- Cynosure News: Todd Tillemans Named New CEOhttps://modernaesthetics.com/news/cynosure-news-todd-tillemans-named-new-ceo/2472869/Todd Tillemans is the new Chief Executive Officer of Cynosure, LLC. Mr. Tillemans is the former President of Hershey's flagship U.S. business generating more than $6.5 billion in annual sales. Prior to that, he held various leadership positions across Unilever's
- Crown Laboratories Restructures after Acquisitionshttps://modernaesthetics.com/news/crown-laboratories-restructures-after-acquisitions/2472866/Crown Laboratories has restructured its commercial operations business units as it continues to elevate its new “Skin Science for Life” commitment. For the past two years, Crown says it has been dedicated to transforming its Northeast Tennessee operations into a global skinc
- AestheticsWire Exclusive: Meet Allē, Allergan’s Upgraded Patient Loyalty Programhttps://modernaesthetics.com/news/aestheticswire-exclusive-meet-alle-allergans-upgraded-patient-loyalty-program/2472858/Allergan’s Brilliant Distinctions customer loyalty program is getting a facelift in honor of its 2nd decade. The program is smarter, faster and now goes by Allē. It’s much more than a new name, shares Carrie Strom, Allergan’s Senior Vice President o
- BTL Files Patent Infringement Lawsuit Against Allergan and Zimmer Related to Emsculpthttps://modernaesthetics.com/news/btl-files-patent-infringement-lawsuit-against-allergan-and-zimmer-related-to-emsculpt/2472855/BTL Aesthetics' US affiliate has filed a lawsuit against Allergan plc, Ireland and its affiliates, and Zimmer MedizinSysteme GmbH, Germany, and its affiliate, in the US Federal District Court for the District of Delaware. The lawsuit asserts
- Ortho Dermatologics Adds Key Staff to Solta Medical Business Unithttps://modernaesthetics.com/news/ortho-dermatologics-adds-key-staff-to-solta-medical-business-unit/2472854/Ortho Dermatologics is staffing up its Solta Medical Business unit. The new appointments include the following: Liz Newman, General Manager, Solta, North America Newman first joined Solta
- ISAPS: Brazil, US Remain Cosmetic Surgery Capitals of the Worldhttps://modernaesthetics.com/news/isaps-brazil-us-remain-cosmetic-surgery-capitals-of-the-world/2472850/Driven by increases in non-invasive procedures, plastic surgery across the globe is on the rise, according to the annual statistics from the International Society of Aesthetic Plastic Surgery (ISAPS), and the US and Brazil remain the cosmetic surgery capitals o
- Revance's DAXI Now One Step Closer to FDA Nodhttps://modernaesthetics.com/news/revances-daxi-now-one-step-closer-to-fda-nod/2472849/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under